Weyerhaeuser - Lots...
Health Care: Drugs
EntreMed Inc. (ENMD: NASDAQ)
$2.01 0.05 | 2.55%
06/18/13 - 04:00 PM ET
Latest Dividend:0.00
Latest Dividend Yield:0.00%
Dividend Ex-Date:12/31/69
Price Earnings Ratio:n/a
Price Earnings Comparisons:
| ENMD | Sector Avg. | S&P 500 |
|---|---|---|
| n/a | 0.00 | 17.70 |
Price Performance History (% change):
| 3 Mo | 1 Yr | 3 Yr |
|---|---|---|
| -16.95 | -1.51 | -63.64 |
| GROWTH | 12 Mo | 3 Yr | CAGR |
|---|---|---|---|
| Revenue | -65.50 | -0.87 | -0.49 |
| Net Income | 0.77 | 0.00 | |
| EPS | -0.36 | 0.00 |
Earnings for ENMD:
| EBITDA | -4.00 |
| REVENUE | 669.31K |
Average Earnings Estimates
| Qtr (03/09) | Qtr (06/09) | FY (12/09) | FY (12/10) | |
|---|---|---|---|---|
| Average Estimate | $n.a. | $n.a. | $n.a. | $n.a. |
| Number of Analysts | 0 | 0 | 0 | 0 |
| High Estimate | $n.a. | $n.a. | $n.a. | $n.a. |
| Low Estimate | $n.a. | $n.a. | $n.a. | $n.a. |
| Prior Year | $-0.10 | $-0.09 | $-0.29 | $n.a. |
| Growth Rate (Year over Year) | n.a.% | n.a.% | n.a.% | n.a.% |
Portfolios with ENMD
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- Contributor6 Drug Stocks Unworthy of B...
- UserBeaver
- Contributor10 Stocks Under $5 Outperfo...
- ContributorStocks Under $5 at Risk of ...
- UserDorkingLad Portfolio 1
- Usersmallbiz
- Usersteves #1
- UserThe Investment Psychologist...
Latest ENMD Headlines from TheStreet
- 7 Stocks Under $10 Making Big Moves Higher 07.05.12 | 02:07 pm
- 6 Drug Stocks Unworthy of Biotech Bull Market 02.07.12 | 12:02 pm
- 5 Stocks Under $10 Poised for Big Upside 02.03.12 | 02:02 pm
- 10 Stocks Under $5 Outperforming in 2012 01.31.12 | 05:01 am
- Stocks Under $5 at Risk of Bankruptcy 06.08.11 | 06:06 am
- Biotech Sector Weekly Rewind 11.20.10 | 08:11 am
- Stock Offerings: Two Harbors 04.19.10 | 10:04 am
- Sprint Nextel, Palm: Early Volume Plays 04.19.10 | 07:04 am
- ThermoGenesis, Power-One: Early Volume Plays 02.05.10 | 07:02 am
- Netlist, EntreMed: Midday Volume Plays 12.14.09 | 02:12 pm
Press Releases for ENMD
- EntreMed Announces Changes To Board Of Directors And CEO Appointment - PR Newswire 04.05.13 | 07:04 am
- EntreMed To Raise $10.7 Million In Registered Direct Offering - PR Newswire 03.01.13 | 08:03 am
- EntreMed Announces Initiation Of Phase 2 Trial In Advanced/Metastatic Soft Tissue Sarcoma - PR Newswire 01.23.13 | 07:01 am
- EntreMed Files New Drug Clinical Trial Application For ENMD-2076 With China SFDA To Advance Global Development Strategy - PR Newswire 01.07.13 | 07:01 am
- EntreMed Announces Initiation Of Second Site For Phase 2 Trial In Triple-Negative Breast Cancer - PR Newswire 01.04.13 | 07:01 am
- PNAS Publishes Preclinical Results Of EntreMed's 2ME2 For Multiple Sclerosis - PR Newswire 12.04.12 | 01:12 pm
- EntreMed Announces Publication Of Preclinical Results For ENMD-2076 In Triple-negative Breast Cancer - PR Newswire 11.26.12 | 07:11 am
- Dana-Farber Cancer Institute's Ursula A. Matulonis, MD Article On EntreMed's ENMD-2076 Published In The European Journal Of Cancer - PR Newswire 09.06.12 | 07:09 am
- EntreMed Announces Initiation Of Phase 2 Trial In Triple-negative Breast Cancer - PR Newswire 07.25.12 | 07:07 am
- EntreMed Appoints Interim CEO - PR Newswire 04.03.12 | 07:04 am
Partner Headlines for ENMD
- Morning Market Movers - Benzinga 11.26.12 | 09:11 am
- Alexandria Leases to NIH - Analyst Blog - NASDAQ 09.07.12 | 08:09 pm
- China Biotech In Review: GSK Explores All Paths To Increase China Presence - Seeking Alpha 03.11.12 | 07:03 am
- China Biotech Week in Review: Shanghai Pharma Plans $1.2 Billion IPO - Seeking Alpha 09.12.10 | 09:09 am
- Big Pharma Looks to Biotech for Innovation - Seeking Alpha 09.12.10 | 08:09 am
- EntreMed Widens Loss in 2Q, Clinical Trials for Ovarian Cancer Progress - Fox Business 08.16.10 | 12:08 pm
